KanekaKANEKA CORPORATION4118東証プライム化学FY ending Mar 2026, consolidated, J-GAAP

Kaneka FY ending Mar 2026 results

About 40% of Kaneka's sales come from Material Solutions Unit, with Nutrition Solutions Unit and Quality of Life Solutions Unit making up much of the rest.

Out of every ¥100 of sales, about ¥4 is left as operating profit.

Revenue changed +0.5% from the prior year, operating profit -17.9%.

Revenue and profit pattern

Revenue up, profit downRevenue grew faster

Revenue +0.5% · profit -17.9%, calculated from disclosed figures.

Operating leverage: -32.50× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2025 → FY ending Mar 2026

Revenue: +0.5%¥807.2B → ¥811.6B
Gross profit: -0.0%¥225.6B → ¥225.6B
Operating income: -17.9%¥40B → ¥32.9B
Net income attributable to owners: +22.4%¥25.3B → ¥31B
Operating cash flow: +21.5%¥41.3B → ¥50.1B
Free cash flow: Loss-¥14.7B → -¥3.26B

Results at a glance

Revenue for the FY ending Mar 2026 was ¥811.6B, up +0.5% from ¥807.2B, so roughly flat.
Operating income dropped from ¥40B to ¥32.9B (-17.9%), as profits shrank in the materials and quality-of-life units.
Net income attributable to owners still grew from ¥25.3B to ¥31B (+22.4%).
Operating cash flow rose to ¥50.1B but did not cover ¥53.4B of capital spending, so free cash flow was -¥3.26B.

What drove the change

The materials unit sold and earned less, hit by weak Asian markets and soft US housing and construction demand
The quality-of-life unit grew sales, but higher raw material costs cut its profit
Health care grew on sales of blood purification devices and catheters, and nutrition grew on supplement ingredients and price increases; both raised sales and profit

Things to watch

Conflict in the Middle East is pushing up oil and naphtha prices and raising supply worries, with a risk of a global slowdown
Many raw materials and fuels are priced on world markets, so unexpected price swings can hurt results
With a large overseas business, sudden currency moves or changes in foreign rules and taxes could affect earnings

Annual Securities Report (102nd term) / MD&A · Annual Securities Report (102nd term) / Business risks

Where the money goes

FY ending Mar 2025 → FY ending Mar 2026

Where ¥100 of sales goes

For every ¥100 Kaneka sells, how much goes where, and how much is kept.

FY ending Mar 2026

Cost of sales: ¥72
SG&A: ¥24
Operating profit: ¥4
Net profit kept: ¥4

Annual margin trends

Gross margin27.8%

Operating margin4.1%

Net margin3.8%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

Material Solutions Unit¥327.2B
40%
Op. margin 7.6%Industry: Chemicals
Nutrition Solutions Unit¥206B
25%
Op. margin 6.7%Industry: Processed Foods
Quality of Life Solutions Unit¥194.3B
24%
Op. margin 9.2%Industry: Textiles & Fibers
Health Care Solutions Unit¥83B
10%
Op. margin 17.9%Industry: Pharmaceuticals
Other¥1.11B
0%
Op. margin 49.7%

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第102期(2025/04/01－2026/03/31)
ID S100YIFD2026-06-24Open
EDINET (FSA Japan)
有価証券報告書－第101期(2024/04/01－2025/03/31)
ID S100W4R92025-06-26Open
EDINET (FSA Japan)
有価証券報告書－第100期(2023/04/01－2024/03/31)
ID S100TV9M2024-06-27Open
EDINET (FSA Japan)
有価証券報告書－第99期(2022/04/01－2023/03/31)
ID S100R8UA2023-06-29Open
EDINET (FSA Japan)
有価証券報告書－第98期(令和3年4月1日－令和4年3月31日)
ID S100OK442022-06-29Open
EDINET (FSA Japan)
有価証券報告書－第97期(令和2年4月1日－令和3年3月31日)
ID S100LKT62021-06-25Open

Extracted from XBRL: 56 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image